Lv7
4440 积分 2021-10-09 加入
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
3天前
已完结
[Chinese expert consensus on diagnosis and treatment of neurologic immune-related adverse events associated with immune checkpoint inhibitors (2022 edition)]
4天前
已完结
Progress in Diagnosis, Treatment and Prediction of Rheumatic Adverse Events Associated with Immune Checkpoint Inhibitors
7天前
已完结
[Expert consensus on immunotherapy for small cell lung cancer (2025 edition)]
10天前
已完结
Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study
16天前
已完结
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
16天前
已完结
免疫检查点抑制剂相关皮肤不良反应诊治中国专家共识（2024版）
17天前
已完结
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
18天前
已完结
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
18天前
已完结
皖公网安备34019202002308
